Follow epoetin indication and dosing restrictions,EMEA says

摘要

Epoetin products should be used strictly in accordance with the indications and dosing recommendations set out in their summaries of product characteristics,the European Medicines Agency (EMEA) has warned this week in a public statement.The EMEA is reviewing the safety of all epoetin products centrally authorised by the agency in light of new data that suggest a possible effect on tumour progression in patients with cancer and an increased risk of serious cardiovascular complications in patients with chronic renal failure.